FIRSTREGULARSESSION
HOUSEBILLNO.1118
103RDGENERALASSEMBLY
INTRODUCEDBYREPRESENTATIVEBROWN(16).
2277H.01I JOSEPHENGLER,ChiefClerk
ANACT
Torepealsection208.176,RSMo,andtoenactinlieuthereoftwonewsectionsrelatingto
abuse-deterrentopioidanalgesicdrugproducts.
BeitenactedbytheGeneralAssemblyofthestateofMissouri,asfollows:
SectionA.Section208.176,RSMo,isrepealedandtwonewsectionsenactedinlieu
2thereof,tobeknownassections208.176and376.1239,toreadasfollows:
208.176.1.ByDecember1,1992,theMOHealthNetdivisionshall,eitherdirectlyor
2throughcontractwithaprivateorganization,provideforaprospectivereviewofdrugtherapy.
3Thereviewshallincludescreeningforpotentialdrugtherapyproblems,duplication,
4contraindications,interactions,incorrectdrugdosage,drugallergy,durationoftherapyand
5clinicalabuseormisuse.
6 2.Anypriorauthorizationrequirementsforopioidanalgesicandanyservice
7denialsmadepursuanttheretoshallnotrequireuseofopioidanalgesicdrugproducts
8withoutabuse-deterrentpropertiesbeforeauthorizingtheuseofabuse-deterrentopioid
9analgesicdrugproducts.
376.1239.1.Asusedinthissection,thefollowingtermsmean:
2 (1)"Abuse-deterrentopioidanalgesicdrugproduct",abrandorgenericopioid
3analgesicdrugproductapprovedbythefederalFoodandDrugAdministrationwith
4abuse-deterrencelabelingclaimsindicatingitsabuse-deterrentpropertiesareexpected
5todeterorreduceitsabuse;
6 (2)"Cost-sharing",anycoveragelimit,co-payment,coinsurance,deductible,or
7otherout-of-pocketpatientexpenserequirements;
EXPLANATION—Matterenclosedinbold-facedbrackets[thus] intheabovebillisnotenactedandis
intendedtobeomittedfromthelaw.Matterinbold-facetypeintheabovebillisproposedlanguage. 8 (3)"Opioidanalgesicdrugproduct",adrugintheopioidanalgesicdrugclass
9prescribedtotreatmoderatetoseverepainorotherconditions,whetherinimmediate
10releaseorextendedlong-actingreleaseformandwhetherornotcombinedwithother
11drugsubstancestoformasingledrugproductorotherdosageform.
12 2.Aninsurancecarrierorhealthplanshallprovidecoverageonitsformulary,
13druglist,orotherlistsofsimilarconstructforatleastoneabuse-deterrentopioid
14analgesicdrugproductperopioidanalgesicsactiveingredient.
15 3.(1)Cost-sharingforbrandnameabuse-deterrentopioidanalgesicdrug
16productscoveredpursuanttothissectionshallnotexceedthelowestcost-sharinglevel
17appliedtobrandnamenon-abusedeterrentopioiddrugscoveredundertheapplicable
18healthplanorpolicy.
19 (2)Cost-sharingforgenericabuse-deterrentopioidanalgesicdrugproducts
20coveredpursuanttothissectionshallnotexceedthelowestcost-sharinglevelappliedto
21genericnon-abusedeterrentopioiddrugscoveredundertheapplicablehealthplanor
22policy.
23 (3)Anincreaseinpatientcost-sharingordisincentivesforprescribersor
24dispensersshallnotbeallowedtoachievecompliancewiththissection.
25 4.Anyprior-authorizationrequirementsorotherutilizationreviewmeasuresfor
26opioidanalgesics,andanyservicedenialsmadepursuantthereto,shallnotrequireuse
27ofopioidanalgesicdrugproductswithoutabuse-deterrentpropertiesinordertoaccess
28abuse-deterrentopioidanalgesicdrugproducts.
âś”
HB1118 2